Acute Myeloid Leukemia (AML) Therapeutics Market Size, Share and Growth Outlook, 2026

Acute Myeloid Leukemia (AML) Therapeutics Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Acute Myeloid Leukemia (AML) Therapeutics Market size is forecast to increase from $3.83 Billion in 2026 to $6.29 Billion in 2034 at a CAGR of 6.4% between 2026 and 2034.

The Acute Myeloid Leukemia (AML) Therapeutics market report provides detailed analysis and outlook of Acute Myeloid Leukemia (AML) Therapeutics segments including By Therapy Class (Chemotherapy, Targeted Therapy, Immunotherapy, Stem-Cell Transplant Support, Supportive Care Drugs), By Mechanism (FLT3 Inhibitors, IDH1, BCL-2 Inhibitors, Hedgehog Pathway Inhibitors, CD33-Directed Antibody–Drug Conjugates), By Patient Demographic (Pediatric, Adult, Geriatric ), By End-User (Hospitals, Specialty Oncology Centers, Academic and Research Institutes) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Acute Myeloid Leukemia (AML) Therapeutics Industry Overview

Targeted Therapies Driving the Evolution of AML Treatment

The Acute Myeloid Leukemia (AML) therapeutics industry is undergoing significant transformation as precision medicine and mutation-specific treatment approaches become central to clinical management. Drug developers are increasingly focusing on molecularly defined AML subtypes, enabling the development of therapies that target specific genetic abnormalities associated with disease progression. Advances in targeted oncology treatments are improving therapeutic options for patients with relapsed or refractory disease while expanding the role of biomarker-driven treatment strategies.

Revuforj® Establishes a New Standard for NPM1-Mutated AML

A major milestone in the AML therapeutics market is the expanded approval of Syndax Pharmaceuticals’ Revuforj® (revumenib). The U.S. FDA granted approval for the use of the menin inhibitor in adult and pediatric patients aged one year and older with relapsed or refractory NPM1-mutated AML. This approval is particularly significant because Revuforj® represents the first approved targeted oral therapy specifically developed for this AML subtype. NPM1 mutations account for approximately 30% of adult acute myeloid leukemia cases, making the therapy highly relevant to a substantial patient population.

Clinical Evidence Supporting Precision Oncology Approaches

The regulatory approval of Revuforj® was supported by findings from the Phase II AUGMENT-101 clinical trial. Trial data demonstrated a complete remission and complete remission with partial hematologic recovery (CR/CRh) rate of 23.1% among treated patients. These results reinforce the growing clinical value of menin inhibition as a therapeutic strategy for genetically defined AML populations. The success of Revuforj® reflects the industry's broader transition toward targeted therapies capable of addressing specific molecular drivers rather than relying exclusively on conventional chemotherapy-based approaches.

Corporate Consolidation Influencing AML Drug Development

Strategic corporate activity is also shaping the competitive landscape of AML therapeutics. Shareholders approved an Arrangement Agreement enabling Hanmi Pharmaceutical to acquire Aptose Biosciences for CA$2.41 per share in cash. In connection with the pending acquisition, Aptose announced its withdrawal from its previous development agreement with CrystalGenomics involving the multi-kinase inhibitor CG-806 (luxeptinib). This decision reflects a strategic effort to consolidate financial and clinical resources around the company's AML-focused development priorities.

Increased Focus on Tuspetinib Development Programs

Following the acquisition agreement, Aptose has concentrated its remaining development efforts on advancing tuspetinib-based AML treatment programs. The company's strategy emphasizes efficient capital allocation and focused clinical execution within the acute myeloid leukemia market. Combined with the emergence of mutation-specific therapies such as Revuforj®, these developments highlight the increasing importance of targeted drug development, precision oncology, and strategic portfolio optimization in shaping the future direction of AML therapeutics.

Acute Myeloid Leukemia (AML) Therapeutics Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Acute Myeloid Leukemia (AML) Therapeutics market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Novartis AG, Pfizer Inc., AbbVie Inc., Bristol Myers Squibb Company, Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Servier Pharmaceuticals, Jazz Pharmaceuticals plc, Agios Pharmaceuticals, Inc., Syndax Pharmaceuticals, Inc.. The Acute Myeloid Leukemia (AML) Therapeutics market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Acute Myeloid Leukemia (AML) Therapeutics industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Acute Myeloid Leukemia (AML) Therapeutics Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Acute Myeloid Leukemia (AML) Therapeutics companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Acute Myeloid Leukemia (AML) Therapeutics markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Acute Myeloid Leukemia (AML) Therapeutics Market Competitive Benchmarking and Company Analysis

Leading companies in Acute Myeloid Leukemia (AML) Therapeutics industry include- Novartis AG, Pfizer Inc., AbbVie Inc., Bristol Myers Squibb Company, Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Servier Pharmaceuticals, Jazz Pharmaceuticals plc, Agios Pharmaceuticals, Inc., Syndax Pharmaceuticals, Inc.. The Acute Myeloid Leukemia (AML) Therapeutics market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Acute Myeloid Leukemia (AML) Therapeutics Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Acute Myeloid Leukemia (AML) Therapeutics market remains one of the strongest-performing segments in the country.
The US Acute Myeloid Leukemia (AML) Therapeutics Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Acute Myeloid Leukemia (AML) Therapeutics market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Acute Myeloid Leukemia (AML) Therapeutics industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Acute Myeloid Leukemia (AML) Therapeutics markets

Canada's strong Acute Myeloid Leukemia (AML) Therapeutics sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Acute Myeloid Leukemia (AML) Therapeutics market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Acute Myeloid Leukemia (AML) Therapeutics Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Acute Myeloid Leukemia (AML) Therapeutics market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Acute Myeloid Leukemia (AML) Therapeutics population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Acute Myeloid Leukemia (AML) Therapeutics industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Acute Myeloid Leukemia (AML) Therapeutics market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Acute Myeloid Leukemia (AML) Therapeutics sales through 2034

France Acute Myeloid Leukemia (AML) Therapeutics companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Acute Myeloid Leukemia (AML) Therapeutics Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Acute Myeloid Leukemia (AML) Therapeutics distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Acute Myeloid Leukemia (AML) Therapeutics Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Acute Myeloid Leukemia (AML) Therapeutics market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Acute Myeloid Leukemia (AML) Therapeutics industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Acute Myeloid Leukemia (AML) Therapeutics industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Acute Myeloid Leukemia (AML) Therapeutics Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Acute Myeloid Leukemia (AML) Therapeutics market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Acute Myeloid Leukemia (AML) Therapeutics market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Acute Myeloid Leukemia (AML) Therapeutics Market Segmentation

By Therapy Class
Chemotherapy
Targeted Therapy
Immunotherapy
Stem-Cell Transplant Support
Supportive Care Drugs
By Mechanism
FLT3 Inhibitors
IDH1
BCL-2 Inhibitors
Hedgehog Pathway Inhibitors
CD33-Directed Antibody–Drug Conjugates
By Patient Demographic
Pediatric
Adult
Geriatric
By End-User
Hospitals
Specialty Oncology Centers
Academic and Research Institutes

Top Companies in Acute Myeloid Leukemia (AML) Therapeutics Industry

Novartis AG
Pfizer Inc.
AbbVie Inc.
Bristol Myers Squibb Company
Astellas Pharma Inc.
Daiichi Sankyo Company, Limited
Servier Pharmaceuticals
Jazz Pharmaceuticals plc
Agios Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc.

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025